ReviewJournal of aging research2025
Modulating Ferroptosis in Aging: The Therapeutic Potential of Natural Products.
Review in Journal of aging research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Mitochondrial Dysfunction as a Driver of Neurodegeneration in Parkinson's and Huntington's Disease: Molecular Insights and Emerging Interventions.Molecular neurobiology · 2026Review
- Impact of Oxidative Stress-Driven Ferroptosis in Neurodegeneration.International journal of molecular sciences · 2026Review
- The Role of Ferroptosis in Diabetes Pathogenesis: Therapeutic Implications of Hydrogen Sulfide and Its Reactive Metabolites.Antioxidants (Basel, Switzerland) · 2026Review
- A Multi-Organ Atlas Links Gut Microbial Metabolites to Systemic Redox Changes in Aging Mice.Aging cell · 2026Article
- Immune Aging as a Failure of Programmed Cell Death Coordination.International journal of molecular sciences · 2026Review
- Aging at the Crossroads of Cuproptosis and Ferroptosis: From Molecular Pathways to Age-Related Pathologies and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Ferroptosis: an emerging key mechanism linking aging, surgical and anesthetic exposure to postoperative cognitive dysfunction.Frontiers in immunology · 2026Review
- In Vitro Cytotoxicity Assessment of Leaves of Tieghemella heckelii on Breast (MDA-MB-468), Liver (HepG2), and Prostate (PC3) Cancer Cell Lines.BioMed research international · 2026Article
- Targeting Aging and Diseases Associated with Ferroptosis and Senescence Through Modulation of Iron, Oxidative Stress and Lipid Peroxidation.Antioxidants (Basel, Switzerland) · 2025Review
- Traumatic brain injury-related ferroptosis: current perspectives.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Screening the Active Phytochemicals FromCancer innovation · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging is a multifactorial process driven by accumulating cellular damage. Ferroptosis-an iron-dependent, lipid peroxidation-mediated form of cell death-has emerged as a critical contributor to age-related tissue degeneration. This review synthesizes current evidence linking ferroptosis to key aging hallmarks, including oxidative stress, chronic inflammation, mitochondrial dysfunction, and dysregulated iron metabolism. Central to these interactions is the age-associated decline in antioxidant defenses (e.g., glutathione, glutathione peroxidase 4 [GPx4]) and paradoxical iron dynamics, where systemic deficiency coexists with intracellular overload, promoting reactive oxygen species (ROS) generation via the Fenton reaction. Natural products such as resveratrol, curcumin, and epigallocatechin gallate (EGCG) exhibit promising anti-ferroptotic effects through mechanisms including iron chelation, ROS scavenging, and upregulation of endogenous antioxidants. Preclinical and clinical studies indicate their potential in reducing lipid peroxidation and enhancing cellular resilience in aging contexts. However, challenges such as poor bioavailability and tissue-specific iron dysregulation remain. This review explores how combinatorial approaches-targeting multiple ferroptosis pathways-may offer synergistic therapeutic benefits. Collectively, ferroptosis inhibition emerges as a promising strategy to mitigate age-associated tissue damage and promote healthy aging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.